CBD Study Yields Results at University of Alabama at Birmingham

Spike Bowan Blog Leave a Comment

According to BizJournals.com, University of Alabama at Birmingham is making great strides in the field of CBD oil Research.

BizJournals.com reports:

“Researchers at the University of Alabama at Birmingham have discovered evidence of interactions between cannabidiol oil, known better as CBD oil, with commonly used anti-epilepsy drugs.

The findings, published on Monday in Epilepsia, the journal of the International League Against Epilepsy, show the first indications of a potential drug with CBD oil. The substance is drawing great interest as a treatment for epilepsy.

The UAB Epilepsy Center launched a study of CBD oil in March 2015; the study was designed to test the safety and tolerability of CBD oil, which is a derivative of the cannabis plant. The patients in the 2015 study were receiving therapy for severe, intractable epilepsy in both adults and children. The study had patients taking CBD oil as well as their prescribed anti-epilepsy medicine as well.

The research team examined blood levels of 81 subjects enrolled in the CBD trials, 39 adults and 42 children, for concentrations of their existing medications. The most significant changes were an increase in the level of an anti- seizure medication, named clobazam, and its active metabolite. The changes were outside the accepted therapeutic range for both drugs. In addition, the research showed that a very small number of participants using the anti-seizure medication, had an increase in liver enzymes, indicating the potential for liver damage in a small number of patents.” (Read More)

When it comes to epilepsy, CBD and cannabis therapies are becoming more and more paramount. In this article from Fox on the work of CBD with Epilepsy:

“Researchers are now hailing a compound in marijuana as a “game-changing medication” for epilepsy. Based on testimonials from parents, Orrin Devinsky of NYU’s Comprehensive Epilepsy Center set out to find proof that epilepsy could be treated with cannabidiol (CBD)—and he says he did.

In a 14-week study, 60 kids and teens with a severe form of epilepsy known as Dravet syndrome were given doses of CBD and saw their number of monthly convulsive seizures fall from 12 on average to about six, reports Live Science.

Three patients saw their seizures stop entirely, the researchers say in the New England Journal of Medicine. One downside: Almost all patients who took CBD reported side effects, including vomiting and diarrhea, per Scientific American.

(CBD doesn’t get users high.) But 62 percent of caregivers said the condition of the child in their care improved overall. That’s compared to 34 percent of caregivers of children who took a placebo, who went from having about 15 monthly seizures to about 14.

Given this study and others, Devinsky says it’s “medieval” that marijuana is deemed a Schedule I substance under the Controlled Substances Act. Drugs in this category have “no currently accepted medical use,” according to the Drug Enforcement Administration, but that’s “simply untrue,” he says.

“To put CBD as a Schedule I drug violates scientific data and common sense.” (More on CBD and epilepsy here.)

This article originally appeared on Newser: Marijuana Extract a ‘Game-Changing Medication’ (Read More)